View ValuationAbClon 将来の成長Future 基準チェック /06現在、 AbClonの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長37.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 04AbClon Inc., Annual General Meeting, Mar 23, 2026AbClon Inc., Annual General Meeting, Mar 23, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 30, eunhaeng-ro, yeongdeungpo-gu, seoul South KoreaNew Risk • Nov 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.8b revenue, or US$2.6m).Reported Earnings • Nov 12Third quarter 2025 earnings released: ₩184 loss per share (vs ₩198 loss in 3Q 2024)Third quarter 2025 results: ₩184 loss per share. Revenue: ₩1.57b (up 96% from 3Q 2024). Net loss: ₩3.52b (loss widened 2.8% from 3Q 2024).お知らせ • Oct 03AbClon Inc. announced that it expects to receive KRW 10.799952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture CapitalAbClon Inc. announced private placement of 592,655 convertible preferred shares at a price of KRW 18,223 for gross proceeds of KRW 10,799,952,065 on October 1, 2025. The transaction includes participation from DSC Home Run Fund No. 2 for 214,015 shares, DSC Dominance Fund I for 32,925 shares, Paratus Innovation Growth M&A No. 2 for 246,940 shares, Dongyu Investment Co Ltd. for 49,388 shares, Alpha View Partners Co., Ltd. for 32,925 shares, Winvest Venture Capital for 16,462 shares. The preferred shares are 100% convertible into 592,655 shares at a conversion price of KRW 18,223 from conversion period of November 7, 2026 to October 28, 2030. The preferred dividend rate for the company’s preferred stock is 1.0% per annum. The shares have a restriction period of 1 year. The transaction is expected to close on October 28, 2025. The transaction is approved by board of directors of the company.New Risk • Sep 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (₩3.0b revenue, or US$2.2m).分析記事 • Sep 08Is AbClon (KOSDAQ:174900) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...New Risk • Aug 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩15b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.0b revenue, or US$2.2m).お知らせ • May 20AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.On May 19, 2025, AbClon Inc. closed the transaction.New Risk • May 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩2.3b revenue, or US$1.7m).お知らせ • May 09AbClon Inc. announced that it expects to receive KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.AbClon Inc. announced a private placement to issue 1,400,000 shares at an issue price of KRW 8723 for gross proceeds of KRW 12,212,200,000 on May 9, 2025. The transaction includes participation from Chong Kun Dang Pharmaceutical Corp. for 1,400,000 shares.New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 34% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (₩2.4b revenue, or US$1.6m). Market cap is less than US$100m (₩141.6b market cap, or US$96.9m).お知らせ • Mar 07AbClon Inc., Annual General Meeting, Mar 31, 2025AbClon Inc., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: seminar room, guro-gu, seoul South Koreaお知らせ • Oct 29AbClon Inc. announced that it expects to receive KRW 30.999884504 billion in funding from The Korea Securities Finance Corporation, Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Shinhan Bank, GC Tech Company Limited and another investorAbClon Inc announced a private placement to issue convertible bonds for gross proceeds KRW 20,000,000,000 and 677,166 common shares at price KRW16,244 for gross proceeds KRW 10,999,884,504, for aggregate gross proceeds KRW 30,999,884,504 on October 28, 2024. The notes bear zero interest and matures on November 29, 2029 for Conversion Period starts from November 29, 2025 to October 29, 2029. The transaction is expected to close on November 29, 2024. The transaction includes participation from Mirae Asset Securities Co., Ltd, KB Securities Co., Ltd, NH Investment & Securities Co., Ltd, The Korea Securities Finance Corporation, Shinhan Bank, GC Tech Company Limited and Dayli Bio Healthcare No.6 Start-Up Venture Private Equity Fund Co., Ltd. The transaction was approved by board of directors. The transaction is expected to close on November 29, 2024.分析記事 • Aug 04Here's Why AbClon (KOSDAQ:174900) Can Afford Some DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • May 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Revenue is less than US$5m (₩2.6b revenue, or US$1.9m).分析記事 • Apr 23Is AbClon (KOSDAQ:174900) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Mar 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Revenue is less than US$5m (₩3.0b revenue, or US$2.2m).New Risk • Jun 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 45% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.5b revenue, or US$2.7m).お知らせ • Sep 30AbClon Inc. announced that it has received KRW 11.999976975 billion in funding from Quad Investment Management Corp.On September 28, 2022, AbClon Inc. closed the transaction.お知らせ • Jul 28+ 2 more updatesAbClon Inc. announced that it has received KRW 10 billion in funding from Quad Investment Management Corp.On July 28, 2022, AbClon Inc. closed the transaction.Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩117 loss per share (vs ₩81.00 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: ₩680.0m (down 3.9% from 3Q 2020). Net loss: ₩1.79b (loss widened 68% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.お知らせ • Feb 25AbClon Inc., Annual General Meeting, Mar 29, 2021AbClon Inc., Annual General Meeting, Mar 29, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Feb 24New 90-day low: ₩27,600The company is down 5.0% from its price of ₩28,950 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period.分析記事 • Feb 16Does AbClon (KOSDAQ:174900) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Dec 25The AbClon (KOSDAQ:174900) Share Price Is Up 85% And Shareholders Are Holding OnIf you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...Is New 90 Day High Low • Dec 21New 90-day high: ₩37,250The company is up 3.0% from its price of ₩36,000 on 22 September 2020. The South Korean market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.Is New 90 Day High Low • Nov 11New 90-day low: ₩27,350The company is down 26% from its price of ₩36,750 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 16New 90-day low: ₩30,650The company is down 14% from its price of ₩35,450 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: ₩31,800The company is down 20% from its price of ₩39,800 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、AbClon は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A174900 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20254,714-18,104-14,446-13,829N/A9/30/20253,801-16,225-15,027-14,562N/A6/30/20253,033-16,129-14,854-14,316N/A3/31/20252,315-16,624-16,292-15,744N/A12/31/20242,340-16,302-14,562-14,394N/A9/30/20242,193-18,173-13,576-13,408N/A6/30/20242,072-18,976-14,916-14,819N/A3/31/20242,437-16,525-12,749-12,678N/A12/31/20232,877-12,904-9,534-9,484N/A9/30/20233,005-9,424-8,441-8,352N/A6/30/20233,267-7,782-7,259-7,163N/A3/31/20233,468-8,728-7,470-7,606N/A12/31/20223,404-9,244-7,582-7,492N/A9/30/20223,170-9,759-10,391-10,335N/A6/30/20222,912-8,964-9,471-9,341N/A3/31/20223,262-11,027-9,707-9,013N/A12/31/20213,018-10,238-9,166-8,643N/A9/30/20213,232-9,905-6,170-5,034N/A6/30/20213,260-9,178-6,791-5,717N/A3/31/20212,482-6,731-7,199-4,771N/A12/31/20202,771-6,445-9,089-5,648N/A9/30/20203,196-5,538-9,983-6,546N/A6/30/20203,005-5,132-16,149-3,996N/A3/31/20203,258-4,534-15,257-3,608N/A12/31/201914,3752,567-11,007-450N/A9/30/201914,7584,039N/A5,273N/A6/30/201914,8833,898N/A4,131N/A3/31/201914,7534,802N/A4,484N/A12/31/20183,921-843N/A3,715N/A9/30/20183,031-2,047N/A-1,268N/A6/30/20182,908-1,850N/A-1,369N/A3/31/20183,094-1,578N/A-800N/A12/31/20173,532-1,483N/A-1,115N/A9/30/20173,421-1,644N/A-1,159N/A6/30/20173,497-1,617N/A297N/A3/31/20174,193-951N/A158N/A12/31/20163,120-1,597N/A-205N/A9/30/20163,173-1,949N/A-733N/A6/30/20163,047-1,794N/A-2,318N/A3/31/20161,994-2,767N/A-2,021N/A12/31/20151,948-9,842N/A-2,201N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A174900の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A174900の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A174900の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A174900の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A174900の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A174900の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 00:35終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AbClon Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Wan KuNH Investment & Securities Co., Ltd.Eun Saem LeeShinhan Investment Corp.
お知らせ • Mar 04AbClon Inc., Annual General Meeting, Mar 23, 2026AbClon Inc., Annual General Meeting, Mar 23, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 30, eunhaeng-ro, yeongdeungpo-gu, seoul South Korea
New Risk • Nov 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.8b revenue, or US$2.6m).
Reported Earnings • Nov 12Third quarter 2025 earnings released: ₩184 loss per share (vs ₩198 loss in 3Q 2024)Third quarter 2025 results: ₩184 loss per share. Revenue: ₩1.57b (up 96% from 3Q 2024). Net loss: ₩3.52b (loss widened 2.8% from 3Q 2024).
お知らせ • Oct 03AbClon Inc. announced that it expects to receive KRW 10.799952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture CapitalAbClon Inc. announced private placement of 592,655 convertible preferred shares at a price of KRW 18,223 for gross proceeds of KRW 10,799,952,065 on October 1, 2025. The transaction includes participation from DSC Home Run Fund No. 2 for 214,015 shares, DSC Dominance Fund I for 32,925 shares, Paratus Innovation Growth M&A No. 2 for 246,940 shares, Dongyu Investment Co Ltd. for 49,388 shares, Alpha View Partners Co., Ltd. for 32,925 shares, Winvest Venture Capital for 16,462 shares. The preferred shares are 100% convertible into 592,655 shares at a conversion price of KRW 18,223 from conversion period of November 7, 2026 to October 28, 2030. The preferred dividend rate for the company’s preferred stock is 1.0% per annum. The shares have a restriction period of 1 year. The transaction is expected to close on October 28, 2025. The transaction is approved by board of directors of the company.
New Risk • Sep 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (₩3.0b revenue, or US$2.2m).
分析記事 • Sep 08Is AbClon (KOSDAQ:174900) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
New Risk • Aug 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩15b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.0b revenue, or US$2.2m).
お知らせ • May 20AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.On May 19, 2025, AbClon Inc. closed the transaction.
New Risk • May 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩2.3b revenue, or US$1.7m).
お知らせ • May 09AbClon Inc. announced that it expects to receive KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.AbClon Inc. announced a private placement to issue 1,400,000 shares at an issue price of KRW 8723 for gross proceeds of KRW 12,212,200,000 on May 9, 2025. The transaction includes participation from Chong Kun Dang Pharmaceutical Corp. for 1,400,000 shares.
New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 34% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (₩2.4b revenue, or US$1.6m). Market cap is less than US$100m (₩141.6b market cap, or US$96.9m).
お知らせ • Mar 07AbClon Inc., Annual General Meeting, Mar 31, 2025AbClon Inc., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: seminar room, guro-gu, seoul South Korea
お知らせ • Oct 29AbClon Inc. announced that it expects to receive KRW 30.999884504 billion in funding from The Korea Securities Finance Corporation, Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Shinhan Bank, GC Tech Company Limited and another investorAbClon Inc announced a private placement to issue convertible bonds for gross proceeds KRW 20,000,000,000 and 677,166 common shares at price KRW16,244 for gross proceeds KRW 10,999,884,504, for aggregate gross proceeds KRW 30,999,884,504 on October 28, 2024. The notes bear zero interest and matures on November 29, 2029 for Conversion Period starts from November 29, 2025 to October 29, 2029. The transaction is expected to close on November 29, 2024. The transaction includes participation from Mirae Asset Securities Co., Ltd, KB Securities Co., Ltd, NH Investment & Securities Co., Ltd, The Korea Securities Finance Corporation, Shinhan Bank, GC Tech Company Limited and Dayli Bio Healthcare No.6 Start-Up Venture Private Equity Fund Co., Ltd. The transaction was approved by board of directors. The transaction is expected to close on November 29, 2024.
分析記事 • Aug 04Here's Why AbClon (KOSDAQ:174900) Can Afford Some DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • May 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Revenue is less than US$5m (₩2.6b revenue, or US$1.9m).
分析記事 • Apr 23Is AbClon (KOSDAQ:174900) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Mar 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Revenue is less than US$5m (₩3.0b revenue, or US$2.2m).
New Risk • Jun 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 45% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.5b revenue, or US$2.7m).
お知らせ • Sep 30AbClon Inc. announced that it has received KRW 11.999976975 billion in funding from Quad Investment Management Corp.On September 28, 2022, AbClon Inc. closed the transaction.
お知らせ • Jul 28+ 2 more updatesAbClon Inc. announced that it has received KRW 10 billion in funding from Quad Investment Management Corp.On July 28, 2022, AbClon Inc. closed the transaction.
Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩117 loss per share (vs ₩81.00 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: ₩680.0m (down 3.9% from 3Q 2020). Net loss: ₩1.79b (loss widened 68% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 25AbClon Inc., Annual General Meeting, Mar 29, 2021AbClon Inc., Annual General Meeting, Mar 29, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Feb 24New 90-day low: ₩27,600The company is down 5.0% from its price of ₩28,950 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period.
分析記事 • Feb 16Does AbClon (KOSDAQ:174900) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Dec 25The AbClon (KOSDAQ:174900) Share Price Is Up 85% And Shareholders Are Holding OnIf you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...
Is New 90 Day High Low • Dec 21New 90-day high: ₩37,250The company is up 3.0% from its price of ₩36,000 on 22 September 2020. The South Korean market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Nov 11New 90-day low: ₩27,350The company is down 26% from its price of ₩36,750 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 16New 90-day low: ₩30,650The company is down 14% from its price of ₩35,450 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: ₩31,800The company is down 20% from its price of ₩39,800 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.